Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit.

ABSTRACT:

Background

Alzheimer's disease (AD) is a complex and heterogeneous disease, which requires reliable biomarkers for diagnosis and monitoring disease activity. Preanalytical protocol and technical variability associated with biomarker immunoassays makes comparability of biomarker data across multiple cohorts difficult. This study aimed to compare cerebrospinal fluid (CSF) biomarker results across independent cohorts, including participants spanning the AD continuum.

Methods

Measured on the NeuroToolKit (NTK) prototype panel of immunoassays, 12 CSF biomarkers were evaluated from three cohorts (ALFA+, Wisconsin, and Abby/Blaze). A correction factor was applied to biomarkers found to be affected by preanalytical procedures (amyloid-β_1-42, amyloid-β_1-40, and

SUBMITTER: Johnson SC 

PROVIDER: S-EPMC9883877 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature